LeMaitre Vascular, Inc. Stock Börse Stuttgart

Equities

LHU

US5255582018

Advanced Medical Equipment & Technology

Market Closed - Börse Stuttgart 15:53:08 2024-06-21 EDT 5-day change 1st Jan Change
75.5 EUR +0.67% Intraday chart for LeMaitre Vascular, Inc. +3.42% +45.19%

Financials

Sales 2024 * 215M 201M 294M Sales 2025 * 231M 216M 317M Capitalization 1.83B 1.71B 2.51B
Net income 2024 * 40M 37.41M 54.78M Net income 2025 * 44M 41.16M 60.25M EV / Sales 2024 * 8.51 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 7.91 x
P/E ratio 2024 *
46 x
P/E ratio 2025 *
41.7 x
Employees -
Yield 2024 *
0.79%
Yield 2025 *
0.81%
Free-Float 84.65%
More Fundamentals * Assessed data
Dynamic Chart
1 week+3.42%
Current month+4.14%
1 month+4.86%
3 months+21.77%
6 months+52.22%
Current year+45.19%
More quotes
1 week
74.00
Extreme 74
77.00
1 month
70.50
Extreme 70.5
77.00
3 years
35.60
Extreme 35.6
77.00
5 years
18.80
Extreme 18.8
77.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 92-05-31
President 60 96-12-31
Director of Finance/CFO 59 04-12-31
Members of the board TitleAgeSince
Director/Board Member 58 14-04-08
Director of Finance/CFO 59 04-12-31
Director/Board Member 76 08-09-16
More insiders
Date Price Change
24-06-21 75.5 +0.67%
24-06-20 75 -2.60%
24-06-19 77 +2.67%
24-06-18 75 +0.67%
24-06-17 74.5 +2.05%

Delayed Quote Börse Stuttgart, June 21, 2024 at 03:53 pm

More quotes
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Company’s principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
81.5 USD
Average target price
81.25 USD
Spread / Average Target
-0.31%
Consensus